https://pubmed.ncbi.nlm.nih.gov/39704261/ Primary sclerosing cholangitis

J Pediatr Gastroenterol Nutr. 2024 Dec 20.
doi: 10.1002/jpn3.12443. Online ahead of print.

Determining the time to cholangiocarcinoma in pediatric-onset PSC-IBD

Batul Kaj-Carbaidwala 1, Johan Fevery 2, Douglas G Adler 3, Annika Bergquist 4, Lissy de Ridder 5, Mark Deneau 6, Corinne Gower-Rousseau 7, Roger W Chapman 8, Kate D Lynch 8 9, Catherine A M Stedman 10, David C Wilson 11, Uzma Shah 1, Lipika Goyal 12, Harland S Winter 1, Jochen K Lennerz 13
Affiliations expand
PMID: 39704261

DOI: 10.1002/jpn3.12443
Abstract

Primary sclerosing cholangitis (PSC) is a risk factor for cholangiocarcinoma. When a child is diagnosed with both PSC and inflammatory bowel disease (IBD), evidence-based information on counseling families and risk management of developing cholangiocarcinoma is limited. In this case series (PubMed/collaborators), we included patients with PSC-IBD who developed cholangiocarcinoma and contacted authors to determine an event curve specifying the time between the second diagnosis (IBD or PSC) and a diagnosis of cholangiocarcinoma. Review of n = 175 studies resulted in a cohort of n = 21 patients with pediatric-onset PSC-IBD-cholangiocarcinoma. The median time to development of cholangiocarcinoma was 6.95 years from the second diagnosis. Despite the small number, 38% of cholangiocarcinoma developed within the first 2 years, and 47% of patients developed cholangiocarcinoma in the transition period to adult care (age 14-25). Our findings highlight the importance of screening that extends over the so-called transition period from pediatric to adult care.